Business Wire

TX-FLUENCE

9.5.2022 14:02:07 CEST | Business Wire | Press release

Share
Fluence Illuminates Wageningen University & Research’s Autonomous Greenhouse Challenge With VYPR Top Lights and Wireless Flex Dimming

Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its sponsorship of Wageningen University & Research’s (WUR) third Autonomous Greenhouse Challenge in the Netherlands. For the first time in the challenge’s history, WUR leveraged a broad-spectrum LED-only lighting system—specifically Fluence’s VYPR 3p solution—instead of high-pressure sodium (HPS) fixtures. WUR also implemented Fluence’s innovative lighting control solution, Wireless Flex Dimming, into the facility.

Wageningen University & Research is dedicated to researching the future of agriculture by exploring autonomous greenhouse technology, climate control, crop modeling, advanced sensors, data intelligence, computer vision and robotics. Beginning in June 2021, WUR organized its third Autonomous Greenhouse Challenge to task different international teams with sustainably growing vegetables in a fully automated greenhouse environment.

“We expect that food production in greenhouse horticulture can be further improved by adding more artificial intelligence to the agricultural industry,” said Silke Hemming, who leads the scientific research team for greenhouse technology at WUR, in a statement . “We make connections with international partners through this unique challenge, so that we can take major steps.”

One of the challenges growers face when transitioning from HPS to LED luminaires is that a typical HPS system is limited in its dimming capabilities, unlike LED technology. By leveraging state-of-the-art, qualified Bluetooth mesh technology enabled by Technology Partner SILVAIR, Fluence’s Wireless Flex Dimming solution allows growers to have precise control of dim light levels. By connecting the VYPR top light fixtures to the climate computer through Wireless Flex Dimming, the participants were empowered to implement advanced lighting control strategies that maximized plant growth and quality.

“In any greenhouse or controlled environment, the reliability of a cultivation system is paramount,” said Theo Tekstra, Fluence’s technical director for Europe, Middle East and Africa. “Wireless Flex Dimming enables growers to simplify installation and gain solid wireless control of their light levels, whether in an autonomous scientific experiment or a large-scale greenhouse. We are now implementing this technology for customers with more than 7,000 connected fixtures.”

WUR’s Autonomous Greenhouse Challenge also seeks to discover how artificial intelligence can play a role in the future of cultivation, including how to reduce energy input and cost.

“The complete cultivation process is handled by AI and algorithms developed by the teams,” Tekstra added. “One important input factor is the strong fluctuations in high energy prices. Fluence’s Wireless Flex Dimming integration with the Ridder climate computer allows the teams to modulate the lights within their lighting strategy algorithms to optimize energy costs. Fluence’s mission is to help the world grow smarter—something these incredible teams are tackling head-on. We are delighted to support WUR and this initiative with our advanced lighting solutions.”

Fluence continues to demonstrate how secure, intelligent lighting solutions based on the latest technology innovations can add value to the global horticulture industry. The Wireless Flex Dimming Receiver has been awarded PSA Certified™ Level 1 (an independent measurement of security best practices spearheaded by Arm) from Riscure. PSA Certified is recognized by the DesignLights Consortium as an approved cybersecurity standard for networked lighting control systems.

Results from the challenge will be published in July 2022. To follow the competing teams’ progress, visit WUR’s greenhouse challenge dashboard here . For more information on Fluence and its portfolio of controls and luminaires, visit www.fluence.science .

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye